Anaemia is a common manifestation of chronic kidney disease, especially when the glomerular filtration rate falls below 30 ml/min. It is important to exclude other causes of anaemia such as iron and other haematinic deficiencies, chronic inflammation, malignancy and drugs. After reversible causes of anaemia are excluded, supplementary erythropoietin (epoetin) can be considered when the patient's haemoglobin concentration falls below 100 g/l. Patients treated with epoetin often require supplements of oral or intravenous iron to maintain adequate iron stores during the correction and the maintenance phases of management. The main adverse effect of epoetin use is the development or worsening of hypertension. Care must also be taken not to overshoot the target haemoglobin of 110-120 g/l, as this can be associated with a prothrombotic tendency.
Introduction
Erythropoietin is a hormone made predominantly within the peritubular cells of the kidney. It acts on the bone marrow, stimulating erythropoiesis. Erythropoietin also controls apoptosis (programmed cell death) of mature red blood cells.
Renal disease reduces erythropoietin production.
The management of anaemia in chronic kidney disease has been revolutionised by the development of recombinant human erythropoietin (epoetin). 1 Many of the symptoms that had been ascribed to chronic kidney disease such as fatigue, lethargy, somnolence and shortness of breath, which all impact unfavourably on quality of life, were resolved or markedly improved when anaemia was corrected. 2 Before the development of epoetin, uraemic anaemia was managed by recurrent blood transfusions, with the risk of iron overload and viral infection (hepatitis B and C and HIV).
uraemic anaemia
Although uraemic anaemia can be present when the glomerular filtration rate is above 30 mL/min, it is more prevalent when the rate falls below 30 mL/min (stages four and five chronic kidney disease). Patients with diabetic nephropathy or analgesic nephropathy (who took Bex, Vincent's or APC powders during the 1950s and 1960s) tend to be more anaemic than patients with other causes of chronic kidney disease. In contrast, patients with adult-onset polycystic kidney disease often maintain their haemoglobin concentrations as renal failure progresses. Iron deficiency is common in chronic kidney disease because of the widespread use of antiplatelet drugs (aspirin and clopidogrel), and a possible uraemic platelet defect, enhancing gastrointestinal blood loss. 3 Endoscopy should be considered to exclude gastrointestinal lesions. Haemodialysis patients are also exposed to heparin at least three times per week to prevent clotting on dialysis and a certain amount of blood is lost in the artificial kidney during each haemodialysis session.
Diagnosis of iron deficiency
If the patient has a low haemoglobin, iron studies are indicated.
Serum ferritin is a marker of iron stores but can be elevated as an acute phase reactant, similar to C-reactive protein and erythrocyte sedimentation rate. Transferrin saturation reflects iron availability in the bone marrow. Both measurements are needed to assess iron status accurately. Serum iron is subject to diurnal variations in concentration and is not a useful marker of iron status in chronic kidney disease.
There is a chronic inflammatory state in patients with chronic kidney disease so the normal ranges for serum ferritin and transferrin saturation do not apply. Absolute iron deficiency cannot be excluded unless the ferritin is greater than 100 microgram/L or the transferrin saturation greater than 20%. 
Which supplementary epoetins are available?
Since the original epoetin alfa was released, there have been different molecular modifications including increased numbers of sialic acid residues, carbohydrate moieties or pegylation.
These modifications increase the half-life of the epoetins and reduce the dosage frequency. All currently available epoetins correct anaemia to the same extent. The choice is dictated by the preferred frequency and route of administration (subcutaneous or intravenous).
All epoetins are subject to degradation if not refrigerated. Care must be taken when transporting epoetin from hospital or community pharmacies to the patient's home.
Epoetin alfa
This epoetin was released onto the Australian market in 1989.
It has been extensively studied in trials since then. Originally it was given three times per week, but can be extended to weekly administration. Several years ago over 200 patients worldwide developed pure red cell aplasia secondary to the development of anti-erythropoietin antibodies. This manifested as severe transfusion dependent anaemia because the injected epoetin and any native erythropoietin were destroyed by these antibodies.
Epoetin beta
This epoetin has a similar pharmacological profile to epoetin alfa. Recently it has been shown to be less painful than darbepoetin alfa when injected subcutaneously. 7
Darbepoetin alfa
This product has a much longer duration of action than the epoetins. The dosing schedule can be extended to monthly administration during the maintenance phase in patients who do not need dialysis. Whether the drug is administered intravenously or subcutaneously makes no difference to its efficacy in maintaining haemoglobin concentrations.
Methoxy polyethylene glycol-epoetin beta
This product has not as yet been released in Australia. It is a pegylated epoetin with a different mode of receptor activation. This further extends the dosing interval so that it can be administered monthly during either the correction or maintenance phase irrespective of whether or not the patient is having dialysis.
Biosimilar epoetin alfa
A biosimilar is a product which is similar to a biological product which is similar to a biological medicine that has already been approved by the regulatory agencies but whose patent has typically expired. . 
What monitoring needs to be undertaken?
During the correction phase of anaemia, blood pressure should be monitored monthly and the haemoglobin concentration every 4-6 weeks. Hypertension is associated with a rapid rise in haemoglobin from baseline so the target rate of rise is 10 g/L/month. Iron studies should be checked at least once every two months, but this recommended frequency of monitoring has not been subject to clinical trial verification. Consultation with nephrology services is required during the correction phase, but monitoring of haemoglobin in the maintenance phase is often undertaken by general practitioners. In this setting, the frequency of haemoglobin monitoring can be extended to every 2-3 months, with iron studies every three months.
Conclusion
Anaemia is common in patients with chronic kidney disease.
Other causes of anaemia should be excluded. Iron deficiency should be corrected, but if the haemoglobin falls below 100 g/L, treatment with a recombinant epoetin should be considered.
This will correct the uraemic anaemia and maintenance therapy will be required once the target haemoglobin has been achieved. If epoetin is stopped, the haemoglobin falls back towards baseline. Correcting the anaemia can improve the patient's quality of life.
